Switzerland· 69553001

Andembry

A garadacimab product containing garadacimabum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC B06AC07

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedAndembryATCB06AC07REGISTER NO.69553001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Garadacimab is registered in 11 of 19 countries.

Countries holding a registration under ATC B06AC07 (garadacimab), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Garadacimab · ATC B06AC07

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
garadacimabum
Manufacturer
—
Country
Switzerland (CH)
ATC code
B06AC07
ATC class
Garadacimab
Defined daily dose
6.7 mg, P
Swissmedic category
B
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680695530018
    1.2 ml
    CHF 16158.45

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Garadacimab in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All garadacimab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Andembry
  • Liechtenstein · Andembry
  • Norway · Andembry

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b18ca5a2-21f9-44c2-a35b-a1d0d70aed83
GET /v1/drugs/b18ca5a2-21f9-44c2-a35b-a1d0d70aed83?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "garadacimabum 200 mg",
  "valid_from": "2025-09-01",
  "limitations": "[{\"description\":\"Nach Kostengutsprache des Krankenversicherers mit vorgängiger Konsultation des Vertrauensarztes resp. nach Kostengutsprache durch die IV-Stelle nach vorgängiger Konsultation des regionalärztlichen Dienstes (RAD).<br>\\nANDEMBRY wird vergütet als Monotherapie zur <b>Langzeitprophylaxe</b> wiederkehrender akuter Schübe des hereditären Angioödems (HAE) vom Typ I oder Typ II bei Patienten ab einem Alter von 12 Jahren, die trotz on-demand Behandlung einen nachweislich schweren Verlauf UND ≥ 2 Attacken pro Monat über einen Zeitraum von 12 Monaten verzeichnen.<br>\\nDie Einleitung und Überwachung der Behandlung erfolgt ausschliesslich über eines der folgenden Zentren: Universitätsspital Zürich, Inselspital Bern, Universitätsspital Basel, CHUV, HUG, Kantonsspi-tal Luzern, Kantonsspital Aarau und Kantonsspital St. Gallen, Hôpital du Valais (Institut Central des Hôpitaux (ICH) Sion und Ospedale Regionale di Bellinzona e Valli.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-09-01\",\"validTo\":\"2028-08-31\"}]",
  "galenic_form": "Inj Lös 200 mg/1.2ml Fertpen",
  "therapeutic_area": null,
  "sl_inclusion_date": "2025-09-01",
  "self_retention_pct": 10
}

See everything about garadacimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.